# Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

> **NCT02717091** · PHASE2 · UNKNOWN · sponsor: **Nagoya University** · enrollment: 50 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Cancer

## Interventions

- **DRUG:** FOLFIRINOX
- **DRUG:** gemcitabine + nab-paclitaxel

## Key facts

- **NCT ID:** NCT02717091
- **Lead sponsor:** Nagoya University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2020-06
- **Final completion:** 2023-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717091, "Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02717091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*